Drugs News and Research

RSS

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

Cyclacel Pharmaceuticals, Inc., today announced that it has opened enrollment of the SEAMLESS pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment of elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

11 Jan 2011

Swedes are consuming less alcohol

Despite the fact that the Swedish Alcohol Retail Monopoly's sales are rising and statistics from Statistics Sweden indicate that we drink more and more alcohol, the trend is going in the opposite direction - Swedes' alcohol consumption is falling. This emerges from the Consumption Report 2010 (Konsumtionsrapporten 2010) published by the Centre for Consumer Science at the University of Gothenburg.

11 Jan 2011

Mithridion secures commitments of $1.25 million in new funding

Mithridion, Inc., a privately-owned clinical stage drug development company focusing on serious Central Nervous System disorders, including Alzheimer's disease, announces that it has secured commitments of $1.25 million in new funding.

11 Jan 2011

Positive results from Allovectin-7 Phase 3 trial in patients with metastatic melanoma

Vical Incorporated today announced a new publication summarizing results from the company's completed trials of Allovectin-7 including systemic responses and an excellent safety profile in patients with metastatic melanoma.

11 Jan 2011

First commercial deployment of Hotspur GPSCath Balloon Dilatation Catheter

Hotspur Technologies, Inc. announced today that Dr. Bruce Lin, M.D., and Dr. Stephen Liu, M.D., Interventional Radiologists at Lifelink Interventional Center in Modesto, California, performed the first commercial deployment of the company's GPSCath™ Balloon Dilatation Catheter.

11 Jan 2011

Scientists create particles that resemble RBC, pave way for development of synthetic blood

A team of scientists has created particles that closely mirror some of the key properties of red blood cells, potentially helping pave the way for the development of synthetic blood.

11 Jan 2011

Bioheart announces primary focus on completing clinical evaluation of cell therapies for heart failure

Bioheart, Inc. announced today that Bioheart's primary focus is on completing clinical evaluation of its cell therapies for treating heart failure and related cardiac diseases.

11 Jan 2011

Basal-like breast cancer is equally aggressive disease in African American women and white women: Study

In 2006, a team from the University of North Carolina at Chapel Hill schools of Public Health and Medicine and UNC Lineberger Comprehensive Cancer Center found that breast cancer in younger African American women is more likely to be the more aggressive basal-like (or triple-negative) subtype - one factor thought to be behind known racial disparity differences in breast cancer patient outcomes.

11 Jan 2011

Study identifies over 30 breast cancer gene targets involved in drug resistance to chemotherapy

A new study conducted by Josh LaBaer's research team in the Biodesign Institute at Arizona State University has pinpointed more than 30 breast cancer gene targets ---including several novel genes---that are involved in drug resistance to a leading chemotherapy treatment.

11 Jan 2011

Health centers should screen students for depression

One out of every four or five students who visits a university health center for a routine cold or sore throat turns out to be depressed, but most centers miss the opportunity to identify these students because they don't screen for depression, according to new Northwestern Medicine research.

11 Jan 2011

QIAGEN to acquire minority stake in Alacris Theranostics

QIAGEN has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient's genomic profile, and for the acquisition of an exclusive option to access all biomarkers emerging from this discovery program.

From QIAGEN Manchester Limited 11 Jan 2011

Biologics receives National Comprehensive Cancer Network recognition

Biologics, Inc., an oncology management company, has been recognized by the National Comprehensive Cancer Network® (NCCN®) for its commitment to supporting patient access to quality oncology care. For the first time, the NCCN, a not-for-profit alliance of 21 of the world's leading cancer centers, is recognizing commercial payor and non-payor organizations, including Biologics, which support the appropriate, effective, and efficient use of oncology treatment and care of patients through its new NCCN Recognition Program.

11 Jan 2011

Silicon microdevices may provide new way to screen metastatic breast cancer cells

Research by engineers and cancer biologists at Virginia Tech indicate that using specific silicon microdevices might provide a new way to screen breast cancer cells' ability to metastasize.

11 Jan 2011

Plasminogen may serve as new target to treat prion diseases

Scientists at the University of Kentucky have discovered that plasminogen, a protein used by the body to break up blood clots, speeds up the progress of prion diseases such as mad cow disease.

11 Jan 2011

Predator microbes may work against antibiotic resistant disease-causing bacteria: Study

There are predators in the bacterial world that consume other bacteria, much as predators attack prey in the animal world. A team led by researchers at the University of Medicine and Dentistry of New Jersey-New Jersey Dental School suggests that some of these predator microbes might be put to work against disease-causing bacteria that have become resistant to antibiotics.

11 Jan 2011

Enlight Biosciences forms new oral drug delivery technology company

Entrega, Inc., a new company developing oral drug delivery technologies, today announced its formation by Enlight Biosciences, a Boston-based company established in partnership with a group of leading global pharmaceutical companies.

10 Jan 2011

All fat cells not the same

All fat cells are not the same - a fact that has implications in the understanding and treatment of type 2 diabetes and obesity, said researchers from Baylor College of Medicine (www.bcm.edu) in a report that appears in the current issue of the Journal of Cell Biology (http://www.jcb.rupress.org/).

10 Jan 2011

Obama administration sides with drug companies in pricing lawsuit; Supreme Court agrees to hear case regarding use of prescription drug data

At issue are charges to public hospitals and clinics that treat a large number of poor patients and a Vermont law that restricts prescription drug data.

10 Jan 2011

New study finds extending term of exclusive access can lead to higher drug costs in short term

A new study in the January 2011 issue of Health Affairs is the first to calculate the financial and social costs of limiting access to trial data — and finds that extending the term of exclusive access will lead to higher drug costs in the short term but also to more than 200 extra drug approvals and to greater life expectancy in the next several decades.

10 Jan 2011

Resveratrol stimulates expression of adiponectin hormone: Study

Resveratrol, a compound in grapes, displays antioxidant and other positive properties. In a study published this week, researchers at the UT Health Science Center San Antonio describe a novel way in which resveratrol exerts these beneficial health effects.

10 Jan 2011

Drugs News and Research

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

Swedes are consuming less alcohol

Mithridion secures commitments of $1.25 million in new funding

Positive results from Allovectin-7 Phase 3 trial in patients with metastatic melanoma

First commercial deployment of Hotspur GPSCath Balloon Dilatation Catheter

Scientists create particles that resemble RBC, pave way for development of synthetic blood

Bioheart announces primary focus on completing clinical evaluation of cell therapies for heart failure

Basal-like breast cancer is equally aggressive disease in African American women and white women: Study

Study identifies over 30 breast cancer gene targets involved in drug resistance to chemotherapy

Health centers should screen students for depression

QIAGEN to acquire minority stake in Alacris Theranostics

Biologics receives National Comprehensive Cancer Network recognition

Silicon microdevices may provide new way to screen metastatic breast cancer cells

Plasminogen may serve as new target to treat prion diseases

Predator microbes may work against antibiotic resistant disease-causing bacteria: Study

Enlight Biosciences forms new oral drug delivery technology company

All fat cells not the same

Obama administration sides with drug companies in pricing lawsuit; Supreme Court agrees to hear case regarding use of prescription drug data

New study finds extending term of exclusive access can lead to higher drug costs in short term

Resveratrol stimulates expression of adiponectin hormone: Study

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News